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1. Introduction
 
   Ovarian cancer is one of the most common malignant 
cancer among women. It causes higher mortality than any 
other gynecological malignat tumors. About 70% of the 
patients are found to have been in advanced-stages (Stage 
III and IV) by the time of diagnosis. And 70% of the patients 
have recurrence eventhough they go through primary 
cytoreductive surgery and chemotherapy. With the alteration 
of life style, increasing envirenmental pollution, application 
of assisted reproductive technique and oversue of ovulation 
drugs, the morbidity of ovarian cancer is increased year by 
year. Hence, It is urgent to seek diagnosis methods with 
good sensitivity and high specificity for ovarian cancer, and 
to enhance the diagnosis of primary and reoccurent ovarian 
cancer, which in turn helps in timely and accruate detection 
and treatment of the disease. 
   At present diagnosis of ovarian cancer commonly 
relies on the detection of CA125 in blood serum. However, 
CA125 concentration is increased in only 50%-60% stage 
I patients[1]. As a single marker, its positive predictive 
value is even less than 10%, and this value could be only 
up to 20% in combination with ultrasonic inspection, not to 
mention the possibility of false positive results. Hence, to 
eliminate the weakness of CA125 diagnosis, the discovery 
of new overial tumor biomarkers with high sensitivity and 
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Objective: To study the value of the differentially expressed proteins from primary and recurrent 
ovarian cancer serum for early diagnosis of primary and recurrent ovarian cancer. Methods: 
WCX kit (Bruker Daltonics GraBH) and matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF-MS) technology were used to detect serum samples from 49 
patients with primary ovarian cancer and 21 patients with recurrent disease. Results: In the mass 
range (Mr) from 1 000 to 12 000 Da, eight differentially expressed protein peaks were screened 
from primary ovarian cancer serum. Among them, four protein peaks with Mr 1 457, 1 857, 2 202, 
7 761 were lowly expressed and the others with Mr 2 946, 5 333, 5 859, 5 901 were highly expressed. 
Ten diferentially expressed protein peaks were screened from recurrent ovarian cancer serum. 
Among them, 1 944, 1 980, 2 080, 2 661, 2 993, 4 450, 4 659, 5 359 Da protein expressions were 
increased significantly, and 1897, 7868 Da protein expressions were decreased significantly. The 
pattern of primary ovarian cancer was applied to 8 early-stage ovarian cancer serum samples, 
and 7 serum samples were successfully predicted with the accuracy of 87.5%. The pattern of 
recurrent ovarian cancer was applied to 9 without pelvic or abdominal mass recurrent ovarian 
cancer serum samples, and 8 serum samples were successfully predicted with the accuracy of 
88.9%. Conclusions: Combination of MALDI-TOF-MS and WCX kit technology can directly screen 
the diferrential expressed protein from primary and recurrent ovarian cancer serum. They have 
clinical significance for enhancement of sensitivity and specificity of ovarian cancer diagnosis. 
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specificity is the key for early diagnosis and monitoring. 
   To the best of our knowledge, it is rarely reported 
around the world about the application feasibility of WCX 
kit(Bruker Daltonics GraBH) in commbinition with matrix-
assisted laser desorption/ionization time-of-fligh-t mass 
spectrometry (MALDI-TOF-MS) technology. For this reason, 
the present study combined these two technologies to detect 
the diferentially expressed protein peaks in the serum of 
control group and patients with primary and reoccurent 
ovarian cancer so as to build a diagnosis model with higher 
sensitivity and specificity, and to decrease the mortality 
from ovarian cancer. 
2. Materials and methods
2. 1. Patients 
2. 1. 1. Primary ovarian cancer group
   A total of 49 primary epithelial ovarian cancer patients 
admitted from September 2007 and May 2009 were selected, 
who all underwent surgery and pathological diagnosis, and 
were initial cases without any other complications. 
   According to International Federation of Gynecology 
and Obstetrics pathological staging, the number of cases 
in stage I, stage II, stage III and IV were 3, 5, 30 and 11, 
respectively. The age of the patients ranged from 38-83 years 
old, with an averange of 55.7 years. The positive control 
group consisted of forty patients who underwent surgery and 
were pathologically diagnosed as benign cystic ovarian at 
the same period of time with age range from 30-77 years old 
and averange age of 52.6 years. The normal control group 
consisted of forty healthy patients who underwent physical 
examination with age range from 32-76 years old and 
averange age of 52.8 year. The age of these tree groups was 
not significantly different (P>0. 05). 
2. 1. 2. Recurrent ovarian cancer group
   A total of 21 patients who had recurrence of ovarian 
cancer 6 months after comprehensive treatment and 
clinical complete response were screened. The diagnosid 
standards were 1) The increase of CAI; 2) the occurrence 
of pleural and ascitic fluid; 3) the detection of tumor by 
physical examination; 4) the detection of tumor by imaging 
technique; 5) intestinal obstruction with unknown causes[2]. 
Tumor would be considered to be recurrent as long as 
two situations above occurred. The age range of recurrent 
ovarian cancer group was 34-82 years old with average of 53 
years. The number of cases in stage I, stage II, stage III and 
IV was 3, 4, 8, 6, respectively. Among them, 9 had serous 
cystadenocarcinoma, 4 had mucinous cystadenocarcinoma, 4 
had clear cell carcinoma, 4 had undifferentiated carcinoma. 
And 12 cases were in midium differentiation level, 9 in low 
differentiation level. 
   All patients underwent surgery upon the diagnosis and 
were validated pathologically after the surgery. They had 
standard chemotherapy treatment for at least 6 courses. 
Eighteen patients with complete clinical remission who 
randomly visited our hospital at the same period were 
selected as control. The age range was 42-70 years old, with 
average of 61 years. There was no significant age difference 
between these two groups (P>0. 05). 
2. 2. Chemicals and instrument
   M B - W C X  k i t  ( N o .  2 2 3 9 8 3 ) ,  t a r g e t  f o r  M T P -
Anchorchip800/384 and MALDI-TOFMS were all from Bruker 
Dahonics Ltd (Germany). Acetone, methanol, isopropanol, 
acetonitrile, trifluoroacetic acid, methanoic acid, etc were all 
of HPLC level and purchased from TEDIA, USA and Schadau, 
Spanish. Substrate was freshly prepared by dessolving HCCA 
(Bruker Dahonics, Germany) in ethanolalcohol: acetone (2:1) 
solvent to a concentration of 0. 3 mg/mL. 
2. 3. Blood serum sample collection
   The fasting blood was collected from patients with primary 
ovarian cancer, benign ovarian tumor, recurrent ovarian 
cancer (before the second line chemotherapy or secondary 
cytoreductive surgery), the normal control and patients who 
had an clinical complete remission. The blood was then 
refrigerated within 30 min at 4 曟 for 2 h, centrifuged at 4 曟 
for 20 min at 12 000 rpm. The obtained serum was placed in 
EP tubes and kept in refrigerator at -80 曟 until use. 
2. 4. Blood sample processing procedure
   The processing procedures of the blood sample were 
as the following steps: 1)The suspension of weak cationic 
magnetic beads were throughly mixed up by fluctuating 
the tube; 2) Ten 毺L binding solution of magnetic bead-
based WCX+10 毺L MB-WCX_beads was added into 
200 毺L PCR tube, mixed up by pipetting up and down, then 
5 毺L of blood serum were added, pipetting up and down for 
at least 5 times, inculbated the tube for 5 min; 3) The PCR 
tube was then placed in magnetic bead separator (MBS) for 1 
min, the unbound solution were discarded without touching 
or sucking the magnetic beads; 4)100 毺L of MB-WCX wash 
solution was added into PCR tube, shuttled on MBS for 10 
times. The magnetic beads could be seen attached on the 
wall of tube, and the unbound solution were discarded. This 
procedure was reduplicated twice; 5) The PCR tube was then 
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taken down from MBS, 5 毺L elution solution was added to 
wash the attached magnetic beads by pipetting up and down 
for 10 times. The tube was then put into MBS again, allowing 
the magnetic beads adhering onto the wall of tube, and the 
supernantant was then transferred in an clean centrifuge 
tube. 6) 5 毺L of stablization solution was then added into 
the centrifuge tube and mixed up by pipetting up and down; 
7) 1 毺L of magnetic beads elution solution along with 10 毺
L substrate was totally mixed up and 0. 5-1 毺L injectable 
suspension were spotted onto the target, dried at room 
temperature. 
2. 5. MALDI-ToF-MS detection
   Autoflex control parameters were set as follows: 
LP-Clinprot.  par as the selection methods, MTP-
Anchorchip800/384 as the target, the energy of the laser was 
adjusted to about 60%. The detection mass range (Mr) is 
1 k-12 kDa; The resulting images were analyzed by Autoflex 
analysis and ClinProTools software. 
3. Results
3. 1. Construction of diagnosis model of spectra peak pattern 
for ovarian cancer
3. 1. 1. primary ovarian cancer
   The blood serum protein patterns obtained from patients 
with primary ovarian cancer, benign ovarian tumor and 
the heathy control were analysed and compared using 
ClinProTools software. The group of the neutral/benign 
tumor patiens and the healthy control were combined into 
one group as the expressed blood serum protein patterns 
from this two groups showed no significant variations. In the 
mass range (Mr) from 1 000 to 12 000 Da, eight differentially 
expressed protein peaks were screened (P<0.01 or P<0.05) 
(Table 1). Among them, four protein peaks with Mr 1 457, 
1 857, 2 202, 7 761 were down-regulated and the others with 
Mr 2 946, 5 333, 5 859, 5 901 were up-regulated. These 8 
differential pxpressed protein peaks were built into primary 
ovarian cancer diagnosis model which showed sensitivity 
and speciality for primary ovarian cancer at 95.92% (47/49) 
and 93.75% (75/80), respectively. 
3. 1. 2. recurrent ovarian cancer
   Comparing the recurrent group with the complete clinical 
remission group, ten differentially expressed protein peaks 
were detected in the Mr of 1 000-12 000 Da (Table 2). Among 
them, protein peaks with Mr 1 944, 1 980, 2 080, 2 661, 2 993, 
4 450, 4 659, 5 359 were significantly highly expressed (P<0.01, 
P<0. 05), the protein with Mr 1 897, 7 868, were down-
regulated significantly (P<0. 01). These ten differentially 
expressed protein peaks were built into peak spectral 
diagnosis model for recurrent ovarian cancer. The sensitivity 
and speciacificity of this model is 90.48% (19/21), 83.33% 
(15/18), respectively. 
3. 2. Application of peak spectral diagnosis model for ovarian 
cancer
3. 2. 1. Primary ovarian cancer
   Blood serum of 8 early stage primary ovarian cancer 
patients were treated with the same experimental methods 
and the mass spectra were obtained. Seven cases were 
predicted as ovarian cancer using the diagnosis model 
showing a accuracy of 87.50%. 
3. 2. 2. Recurrent ovarian cancer
   Blood serum of 9 recurrent ovarian cancer patients without 
pelvic or abdominal mass were treated with the same 
experimental methods and the mass spectra were obtained. 
Eight cases were predicted as recurrent ovarian cancer using 
the diagnosis model showing an accuracy of 88.89%. 
Table 1
Mass spectra analysing results of primary ovarian cancer. 
Mr (Da)  Average value 
of the control 
group
Average value 
of the primary 
ovarian cancer 
Significance and trend
1 457.0  49.88    16.74 <0. 05 濝
1 857.0 252.68     57.59 <0. 01 濝
2 202.0 112.51    44.73 <0. 05 濝
2 946.0 211.27    427.79 <0. 01 濜
5 333.0  46.84    122.09 <0. 05 濜
5 859.0  49.35    149.25 <0. 05 濜
5 901.7 149.86 3 026.35 <0. 01 濜
7 761.0 159.65     53.82 <0. 05 濝
Table 2 
The mass spectral analysis results of recurrent ovarian cancer. 
Mr (Da)  Average value 
of the control 
group
Average value 
of the recurrent 
ovarian cancer 
Significance and trend
1 897   29.29   17.68 <0. 01濝
1 944   29.59  282.30 <0. 01濜
1 980   79.55  148.67 <0. 05濜
2 080   31.80   69.83 <0. 01濜
2 661   22.78   48.69 <0. 01濜
2 993   19.63   73.76 <0. 05濜
4 450   13.24   22.01 <0. 01濜
4 659 105.76 206.79 <0. 01濜
5 359   47.82 156.52 <0. 01濜
7 868     2.58     1.42 <0. 01濝
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4. Discussion
   Present researches show that the development of tumor is 
a muti-stage process affected by several factors (including 
envirenmental factor, genetic factor, etc), leading to the 
activation of proto-oncogene and the inactivation of cancer 
suppressor gene. In the invasive development of tumor cells, 
a large number of protein molecules are involved in the 
regulation, apoptosis and transfer. At the early stage of tumor 
without any symtom, the protein level has been changed, 
which could be used as clinical early diagnosis inde. Hence, 
analysing and detecting tumor protein could greatly enhance 
the early detection rate of tumor. 
   Besides recurrent ovarian cancer, the inducement and 
development of malignant tumour is an muti-stage process 
involving a lot of genes. The proto-oncogene is activated 
and the canser suppressor is inactivated under the effect of 
muti-factors. In the aggressive development of tumor cells, 
there is an decrease in cell division regulation machanism 
and increase in the ability to invade towards the surrounding 
tissue and to transfer distantly[3,4]. 
   In the present research, MB-WCX and MALDI-TOF MS 
technologies were employed together to detect the serum of 
49 primary and 21 recurrent ovarian cancer patients. Eight 
differentially expressed protein peaks were screened (P<0.01, 
P<0. 05) from primary ovarian cancer patients compared 
with the control, showing a sensitivity and specificity of 
95.92% and 93.75%, respectively. This protein pattern was 
applied in the prediction of 8 early primary ovarian cancer 
cases, resulting in an accuracy of 87.50%. Ten differentially 
expressed protein peaks were screened (P<0.01, P<0.05) 
from recurrent ovarian cancer patients compared with the 
control, showing a sensitivity and specificity of 90.48% and 
83.33%, respectively. The pattern applied to 9 without pelvic 
or abdominal mass recurrent ovarian cancer serum samples, 
and 8 were successfully predicted with the accuracy of 
88.90%. We could conclude that MB-WCX in conbinition 
with MALDI-TOF MS could have some clinical significance 
in enhancing the diagnosis sensitivity and specificity for 
primary and recurrent overrian cancer. 
   The results from present study is different from other 
studies, in which  combined technologies like SELDI-TOF-
MS, protein chic and SVM was applied to some extent[5,6].
It may be due to the experimental error, but the specific 
machanism remains to be discussed. For the existence of 
such error among studies, some researchers[7] think that it 
is necessary for large-scaled, forwardlooking, multicentric 
clinical experiments so as to validate and standardise this 
technology. 
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